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Interaction of CF Pathogens with Lung Epithelial & Immune cells 
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Chronic bacterial colonization of the airways is the primary cause of morbidity and 
mortality ha patients with CF. We examined ifferent aspects of bacterial host cell 
interactions involving the CF pathogens X aureus, t~ aeruginosa and a range of 
Burkholderia cepacia complex (BCC) strains with lung epithelial mad macr ophage 
cells. The ability of CF pathogens and supernatants from these bacteria to induce 
IL  8 from A549 epithelial cells was examined at various multiplicities of infection 
(MOI) and demonstrated that S. aureus, t~ aeruginosa and BCC strains all had the 
ability to induce IL  8. /~ aeruginosa and BCC strains induced more IL  8 than S. 
aureus (p 0.CCO at an MOI of 1CO:l). Whole cell preparations of all pathogens 
induced greater l vels of IL 8 than their corresponding supernatants. Invasion mad 
intracellular survival properties of S. aureus, 1~ aeruginosa and BCC strains were 
compared in U937 macrophage like c lls. Us ing a modification of the gentamicin 
protection assay, BCC strains demonstrated the highest levels of invasion at all 
MOPs examined (p~).CO 1) although S. aureus was the most resistance to clearance 
by the U937 cells. BCC strains also readily invaded A549 epithelial cells. A quorum 
sensing mutant orB. ceruTcepacia J2315 was created lacking cepl and cepR genes. 
This strain demonstrated significantly less invasion of epithelial A549 cells than the 
wi ld type strain (p 0.CCO) suggesting a role for quorum sensing ha cellular invasion 
by this pathogen. Further understanding of the mechanisms by which these CF 
pathogens induce an ilRqammat ory response and can avoid el imination by the host 
immune system wi l l  ult imately lead to more effective strategies for their control and 
elimination. 
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The exopolysaccharide from cysSc fibrosis-associated Burkholderia 
cepacia complex bacteria: biosynthesis and possible involvement in 
the persistence and virulence of respiratory infections 
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The exopolysaccharide (EPS) Cepacian, produced by 80% of the Burkholderia 
cepacia complex (BCC) cystic fibrosis (CF) isolates obtained from the major 
Portuguese CF Center, was hypothesized to be a persistence mad virulence 
determinant o fBCC assceiated respiratory infections [1]. The 12 genes biosynthetic 
cluster was identified based on the comparison of the nucleotide sequence of the 
plasposon interrupted genes of EPS defective mutants with B. cenocepacia J2315 
genome sequence [2]. These genes may encode glycosyltransferases and enzymes 
required for the formation of nucleotide sugar precursors and polymerization and 
export of Cepacian. 
Based on the ability of the EPS <lefective insertion mutants and the parental mucoid 
strain to form biofi lms in vitro, it was concluded that the EPS is not required for 
biofi lm formation but is involved in the establishment of biofi lms of a larger size, 
presumably enhancing bacterial survival in the CF lung since it is believed that 
sessile bacteria within a biofi lm can more efficiently withstand host immune 
responses mad antibiotic action than planktonic cells. The systematic 
characterization f 108 CF isolates (15 strains of B. cenocepacio recA subgroups A
and B, B. multivorans, B. stabiIis and B. cepacia [3]), has however suggested that 
other strain dependent factors are also involved ha the development of large 
biofi lms ha vitro [1]. This study also indicated that there are other determinants of
persistence and virulence of respiratory infections, depending on both the bacterial 
strain and the host [1]. 
[1] Ckmha et aI JClinMicr obio142:3052/8,2CO4 
[2]Moreir a et aI BBRC 312:323/33,2003 
[3] Ckmha et aI JClinMicr obio141:4113/20,2CO3 
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In vitro and in vivo pathogenicity of Burkholderia cenocepacia strains 
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In the present study, we have aimed at comparing clinical nd environmental 
BurkhoMeria cetuTcepacia strains, belonging to the four recA l ineages, with respect 
to their invasion and infection capacity by memas of ha vitro mad ha vivo CF models. 
We examined 16 genetically unrelated B. cetuTcepacia strains, selected according to 
their origin (environmental and clinical sources), and recA l ineage status. Analysis 
of the distribution of phenotypic traits and genetic markers related to virulence and 
trmasmissibility revealed that some of them are not confined solely to cl inical 
isolates but are also found among environmental isolates. In the in vitro infection 
assays, we used CF mad non CF cells models, infected with B. ce~uTcepacia strains 
and proper negative and positive controls. As in vivo model, we  chosen ma 
established and wel l  characterized mouse agar bead model for cbronic infection. 
Bacterial strains were emMded into the agar beads and applied to the lung of wild 
type mice. According to our prel iminary remits, obtained by employing the clinical 
strain B. ceruTcepacia LMG 16656, no mortality was observed uring the next month 
post infection and quantitative bacteriology of spleens mad liver of infected mice 
revealed that this strain was not invasive. However, it is wel l  adapted to establish a
cbr onic infection and to survive to host defence mechmfism. 
This work was supported by a grant from Italian Cystic Fibrosis Research 
Foutulation (fie), l/?rona, Italy (FFC #II-2004). 
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Investigation of the binding of Burkholderia cepacia to lung epithelial 
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B. cepacia is a gram negative bacteria of which at least nine species have been 
isolated, collectively referred to as the B. cepacia complex (BCC). B. multivorans 
and B. cetuTcepacia are the most clinically relevant. Infections by the BCC cma lead 
to the development of cepacia syndrome causing a rapid decl ine in health, this i  
facilitated by the bacteria's resistance to a spectrum of antibiotics and its ability to 
invade and replicate within epithelial cells and macrophage, ha this study the 
relationship between multiplicity of infection (MOI) and extent of invasion by B CC 
into lung cells was examined using a modified gentamicin protection assay. Four 
lung cell l ines A549 respiratory, Calu 3 bronchial, HBE humma bronchial mad CFBE 
cystic fibrosis bronchial cells were incubated for two hours with strains from the 
BCC using different MOI, bacteria which did not invade were kil led by antibiotics 
and the intracellular bacteria counted. These experiments showed that invasion of 
all four cell l ines was saturable, suggesting invasion is receptor mediated. Binding 
of the bacteria to the mfface of the epithelial cell is the first step in the invasion 
prceess and outer membrmae proteins (OMP) of the BCC may play a role ha this 
prceess. Therefore OMPs were examined via SDS PAGE to identify potential 
receptors/adhesins involved in the binding process. Fluorescent mad DIC 
microscopy are also being used to examine the binding of BCC to lung epithelial 
cells. It is hoped that this study wi l l  demonstrate how B. cepacia interacts with lung 
epithelial cells and help ha the development of new treatments o tackle this ever 
prev lent CF pathogen. 
This project tu~s been funded under the programme for research in thitJ level 
institutions (PRTLI) administered by HEA. 
